Earnings call transcript: Almirall Q1 2026 sees modest revenue miss By Investing.com

Almirall reported Q1 2026 revenue of EUR 291 million, down 1.07% versus the EUR 294.15 million consensus but still up 2.2% year over year, with EBITDA rising to EUR 67.5 million and margin expanding to 23.2%. European dermatology sales grew 19.3% and Ebglyss reached EUR 42 million, though U.S. legacy products remained pressured by generic competition and FX headwinds. The company reiterated full-year guidance and highlighted continued momentum in biologics and dermatology, despite the modest revenue miss.

Analysis

The key second-order read is that the quarter is less about the small top-line miss and more about the quality of mix: dermatology is now carrying the group while legacy U.S. products and FX act as a drag. That changes the equity story from “can they hit guidance?” to “how long can they compound margin while the old book decays?” In that framework, the market is likely underestimating how much incremental EBITDA leverage comes from the European launch curve, especially if SG&A remains phasing-based and not structurally higher.

The bigger risk is that the U.S. portfolio erosion becomes a persistent cash sink just as the company leans into pipeline spend and milestone outflows. The near-term P&L looks resilient because royalty and milestone timing are lumpy, but over the next 2-3 quarters the market will start discounting whether Ebglyss can offset a maturing Ilumetri trajectory and continued legacy decay. If growth decelerates even modestly in the new launches, the multiple can compress quickly because the bullish case is implicitly assuming a multi-year runway with few execution stumbles.

Contrarian angle: consensus may be too focused on the “miss” and not enough on the fact that this is becoming a cleaner dermatology platform with operating leverage. That said, the stock is not obviously cheap if investors are already capitalizing peak sales ambitions without demanding proof on the next wave of assets. The best asymmetry is likely in the peers rather than the headline name: stronger Ebglyss momentum should support the franchise narrative for the class, while companies with more exposed legacy dermatology exposure and weaker pipeline optionality should trade worse as the market re-rates winners and laggards in the category.

From a timing perspective, the next catalyst is not this print but the next 1-2 quarters of launch data and confirmation that U.S. weakness is contained. If Ebglyss keeps accelerating in France/Italy and Ilumetri stays stable, the stock can grind higher; if not, the market will likely rotate to skepticism on the durability of the dermatology premium.

Key Decisions for Investors

• Long ALM on a 3-6 month horizon into the next two quarterly updates; risk/reward is favorable if Ebglyss launch momentum persists, but trim on any sign of sequential deceleration in new-market uptake.
• Pair trade: long ALM / short SNY over 2-4 months. ALM has cleaner near-term dermatology operating leverage, while SNY’s broader exposure leaves it more vulnerable if the market starts rewarding focused execution over scale.
• Relative-value trade: long UCB vs short ALM for the next 6-12 months if you want to express caution on ALM’s valuation. UCB’s pipeline optionality may command a higher scarcity premium if biotech appetite improves, but this is higher beta.
• Use call spreads on ALM rather than outright stock for the next earnings cycle: the catalyst path is positive but the downside is tied to launch execution, FX, and milestone noise that can cap multiple expansion.
• Hedge with a short in a legacy-heavy specialty pharma basket against ALM long exposure; the market is likely to penalize names where dermatology growth is not enough to offset U.S. generic pressure and weaker margin visibility.